Indian Journal of Obstetrics and Gynecology Research, 2019
Abstract
Introduction
Biological reagent like PRP having strong anti-inflammatory and healing effect due to large number of growth factors and paracrine action.
Materials and Methods
single center, prospective observational study at L N Medical College and Research Centre, Bhopal. 120 patients with chronic cervicitis were enrolled; 60 randomly selected patients were given conventional treatment and 60 underwent PRP therapy. PRP was prepared from the patient's own blood and injected immediately in the targeted areas of cervix at 3-4 sites.
Result
Better clinical benefits and healed epithelium were observed on follow-up in the PRP-treated patients compared to conventional treatment, with increased perception of recovery; no complications in either group.
Conclusion
PRP is proposed as a biological, safe, effective option for chronic cervicitis. (Abstract transcribed from the journal HTML page 2026-09-16.)
Topics
DOI 10.18231/j.ijogr.2019.083 10.18231/j.ijogr.2019.083 Khare et al. 2019, Khare 2019
Related articles
sexual-health/vulvovaginal-health/vaginal-atrophy therapeutics/anti-infective-and-anti-inflammatory-agents/immune-modulating-agentsrestorative-reproductive-medicine/adjunct-and-emerging-therapies/platelet-rich-plasma-and-regenerative-approaches
Platelet-rich plasma in the management of vulvovaginal disorders: a systematic review
De Ponte A et al., 2026 · The journal of sexual medicine
[INTRODUCTION] Platelet-rich plasma (PRP) is an innovative tool in regenerative medicine. It is defined as an autologous product obtained by density gradient centrifugation of blood, resulting in a platelet concentrate rich in growth factors. In gynecology, PRP has been used to treat vaginal atrophy, sexual dysfunction, and inflammatory conditions such as vulvar lichen sclerosus. PRP injection into the vulvo-vaginal area is a potential treatment for several conditions; however, treatment methods and applications vary widely across the published literature. [OBJECTIVE] To provide an updated synthesis of current evidence on the administration of PRP to the vulva and vagina as a stand-alone technique in a non-surgical outpatient setting, and to identify its main clinical indications. [METHODS] A systematic search of PubMed and Embase was conducted for studies published up to October 2024 using the terms "platelet rich plasma" AND "vaginal" and "platelet rich plasma" AND "vulvar." Eligible studies included human case reports, prospective, and retrospective cohort studies, as well as randomized and non-randomized controlled trials, assessing PRP injections as a stand-alone technique in the vulvo-vaginal area. Extracted data included study design, patient characteristics, indications, PRP preparation and administration protocols, number of sessions, outcomes, and adverse events. [RESULTS] Eighteen studies met the inclusion criteria: two randomized controlled trials, 10 single-arm clinical trials, one retrospective cross-sectional study, and five case reports, comprising 480 patients (401 treated with PRP). The most frequent indication was vulvar lichen sclerosus (n = 179), followed by sexual dysfunction (n = 133) and vulvovaginal atrophy (n = 87). Protocols varied in preparation methods, injection techniques, and treatment schedules. Across studies, PRP injections were associated with improvements in symptoms, sexual function, and vaginal health, with few and mild adverse events. [CONCLUSION] Current evidence suggests that PRP injections in the vulvo-vaginal area may offer clinical benefits across several indications, with a favorable safety profile. However, the high variability in protocols, small sample sizes, and methodological limitations preclude definitive conclusions. Further high-quality randomized controlled trials are required to establish standardized protocols and confirm efficacy.
therapeutics/anti-infective-and-anti-inflammatory-agents/immune-modulating-agents gynecology/clinical-practice/pharmacology
Open Access
Prospective of low dose naltrexone use in treatment of autoimmune pathology and endometriosis
Golianovskyi OV et al., 2020 · Reproductive Endocrinology
There are still many complex issues in the management of autoimmune pathologies in gynecology and reproductology, endometriosis in particular. Naltrexone, a competitive antagonist of opiate receptors in the central and peripheral nervous systems, reveals new qualities such as effects on autoimmune processes. Naltrexone in low doses of 1.7–5 mg (Low Dose Naltrexone, LDN) revealed the opposite effect on opiate receptors in the form of a rebound effect and, as a consequence, a strong increase in endogenous endorphins and enkephalins. Studies of elevated levels of these neurotransmitters have provided evidence of a multidisciplinary beneficial effect on the immune system of people with endorphin and enkephalin deficiency, an association between the endogenous opiate system and cells and tissue growth in general and healthy immune function was confirmed. The most explored effects of them are such as blocking the synthesis ofpro inflammatory cytokines IL-6, IL-12, tumor necrosis factor, the effect on neuroglia through toll-like receptors, the effect on the cycle cells growth, especially malignant tumor cells, through interaction with opiate growth factor, modulation synthesis of T- and B-lymphocytes. Growing evidence of LDN efficacy is becoming a potentially effective clinical practice in autoimmune pathologies, but still off-label used.Some data of clinical trials is presented. Four studies with Crohn's disease with results of relief of symptoms and remission, including experience in pediatrics. Three clinical trials with LDN results in multiple sclerosis with improved quality of life and improved symptoms. The scientific hypothesis suggests the success of LDN due to the reduction of induced nitric oxide synthase activity. The success of management of patients with malignant tumors is also presented. The article contains the latest data from clinical trials on reported serious and non-serious side effects of naltrexone at various doses, including data confirming the safety of taking mid-therapeutic naltrexone doses throughout pregnancy. These effects of LDN may prove to be effective in management patients with endometriosis.
pregnancy/pregnancy-complications/hypertensive-disorders therapeutics/anti-infective-and-anti-inflammatory-agents/immune-modulating-agentsgenetics-and-immunology/reproductive-immunology/implantation-immunology
Regulatory T cells in human pregnancy: mechanisms, dysregulation, and therapeutic perspectives
Liu H et al., 2026 · Frontiers in immunology
Regulatory T cells (Tregs) play a central role in maintaining immune tolerance and supporting maternal-fetal homeostasis throughout human pregnancy. Clinical and experimental evidence demonstrates that dysregulation of peripheral and decidual Tregs manifested as quantitative deficits, impaired suppressive function or lineage instability increased the risk of various pathological pregnancies, such as recurrent implantation failure (RIF), recurrent spontaneous abortion (RSA), pre-eclampsia (PE) and preterm birth (PTB). Recently, novel therapeutic strategies targeting Tregs have emerged in oncology, transplantation, and autoimmune diseases. However, their application in pathological pregnancy remains in its infancy. This review outlines the spatiotemporal dynamics of peripheral and decidual Tregs throughout gestation, elucidating their roles in maintaining maternal-fetal homeostasis and their dysregulation in pathological pregnancies. We also critically evaluated the therapeutic strategies targeting Tregs and Tregs-associated signaling pathways, including hormonal support, traditional intravenous immunoglobulin, as well as emerging interventions such as immunometabolic reprogramming and engineered cellular therapies like chimeric antigen receptor Tregs. This review may provide insights for understanding the roles of Tregs in physiological and pathological pregnancy, as well as provide new idea in the immunotherapy of pathological pregnancy.
restorative-reproductive-medicine/adjunct-and-emerging-therapies/platelet-rich-plasma-and-regenerative-approaches infertility/ovulation-induction/gonadotropin-therapyreproductive-endocrinology/ovarian-hormones/estrogen
Successful Pregnancy Following Ovarian Platelet-Rich Plasma (PRP) Treatment, the DuoStim Protocol, and Preimplantation Genetic Testing for Aneuploidy in a Patient With Premature Ovarian Insufficiency: A Case Report
Costanzi F et al., 2025 · Cureus
Premature ovarian insufficiency (POI) severely limits reproductive options. We report a successful live birth in a patient with POI following a combined approach of intraovarian platelet-rich plasma (PRP) treatment, double ovarian stimulation (DuoStim protocol), and preimplantation genetic testing for aneuploidy (PGT-A). PRP treatment was performed to restore ovarian function, after which DuoStim was used to maximize oocyte yield. An embryo obtained underwent PGT-A, and transfer of a euploid blastocyst resulted in an uncomplicated pregnancy and the birth of a healthy child. This case highlights the potential of personalized and multidisciplinary strategies to overcome the traditional barriers in POI by integrating regenerative medicine (PRP), advanced ovarian stimulation (DuoStim), and genetic embryo selection (PGT-A). While this innovative approach appears promising for women with diminished ovarian reserve, further studies are needed to confirm its efficacy and safety.